When was Allena founded?

Allena was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Allena located?

Allena is headquartered in Newton, United States. It is registered at One Newton Executive Park Suite 202 Newton, MA 02462.

How many employees does Allena have?

As of Jun 30, 2026, the latest employee count at Allena is 18.

Is Allena a funded company?

Allena is a funded company, having raised a total of $96M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 16, 2011.

When was the latest funding round of Allena?

Allena's latest funding was a $***** Post IPO round on Sep 30, 2020, with participation from 1 investor.

Where does Allena rank among its competitors?

Allena ranks 23rd amongst 110 active competitors, of which 36 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Secretome Therapeutics, which secured $30M in May, 2026.

Who are the top competitors of Allena?

Allena's top competitors include Aurinia Pharmaceuticals, Akebia Therapeutics and Renalys. Among them, Secretome Therapeutics secured the most recent funding round in May, 2026.

Allena - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Allena is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. The company’s approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the bloodstream. Allena’s lead program, ALLN-177, is in an ongoing Phase 2 clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Website: allenapharma.com
Registered Address: One Newton Executive Park Suite 202 Newton, MA 02462

Key Metrics

Founded Year

2011

Location

Newton, United States

Stage

Public

Total Funding

$96M in 5 rounds

Latest Funding Round

Post IPO, Sep 30, 2020, $*****

Investors

HBM Partners & 12 more

Ranked

23^rd among 110 active competitors

Employee Count

18 as on Jun 30, 2026

Similar Companies

Aurinia Pharmaceuticals & 123 more

Exit Details

Public

View Allena's full profile

Allena is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Allena Pharmaceuticals, Inc. CIN: 45-2729920 , United States, Active	Jun 23, 2011	-	21 (As on Dec 31, 2021)	-

Allena got listed on Nov 02, 2017.

Click here to take a look at Allena's IPO in detail

Allena has raised a total funding of $96M over 5 rounds. Its first funding round was on Nov 16, 2011. Its latest funding round was a Post IPO round on Sep 30, 2020 for $*****. 1 investor participated in its latest round. Allena has 13 institutional investors.

Here is the list of recent funding rounds of Allena:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2020	7218327	Post IPO	7974855	5424901	6796380	4807246
Jul 27, 2020	1310231	Post IPO	6338134	5331319	5448153	H.C. Wainwright
Dec 07, 2015	9224984	Series C	7262014	7755434	Partner Fund Management	Frazier Healthcare Partners & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Allena's funding rounds and investors

Allena's employee count trend

Allena has 18 employees as of Jun 26. Here is Allena's employee count trend over the years:

Uncover Allena's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Allena include Aurinia Pharmaceuticals, Akebia Therapeutics and Renalys. Here is the list of Top 10 competitors of Allena, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	VenBio, RA Capital Management & 10 others	67/100
2nd	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Orchard Venture Partners & 13 others	66/100
3rd	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
4th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	60/100
5th	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, 3H Health Investment & 14 others	60/100
6th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	60/100
7th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	60/100
8th	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	59/100
9th	Purespring Therapeutics 2020, London (United Kingdom), Series B	Developer of therapeutics for chronic renal diseases	$164M	Syncona, Sofinnova Partners & 3 others	57/100
10th	Unicycive 2016, San Francisco (United States), Public	Developer of small molecule therapies for the treatment of kidney diseases	$1.55M	Nantahala Capital Management, Walleye & 5 others	55/100
23rd	Allena 2011, Newton (United States), Public	Developer of protein therapeutics to treat nephrology and urological conditions	$96M	Fidelity Investments, Pontifax & 11 others	47/100